# OnCo record nct06021379 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct06021379/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct06021379", "NCT06021379" ;
  schema:name "AryoTrust (AryoGen trastuzumab) post-marketing safety study in HER2-positive breast cancer"@en ;
  schema:alternateName "TRA.ARY.FH.95.IV"@en ;
  schema:description "A safety study of a locally made copy of trastuzumab in 597 Iranian women treated after breast cancer surgery, whose authors judged it generally well tolerated."@en ;
  schema:url <https://onco.cc/trials/nct06021379/> ;
  schema:dateModified "2026-11-04"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT06021379>, <https://doi.org/10.1080/14740338.2024.2385483>, <https://pubmed.ncbi.nlm.nih.gov/39076099/> ;
  onco:status "completed" ;
  onco:phase "observational" ;
  schema:startDate "2017-02-22" ;
  onco:cancers <https://onco.cc/cancers/breast-her2-positive/> ;
  onco:technologies <https://onco.cc/technologies/biosimilar-manufacturing/> ;
  onco:targets <https://onco.cc/targets/her2/> ;
  onco:drugs <https://onco.cc/drugs/trastuzumab/> ;
  onco:companies <https://onco.cc/companies/aryogen-pharmed/> ;
  onco:terms <https://onco.cc/terms/biosimilar/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-aryotrust-trastuzumab-pms-2024/> .